Avirup Chowdhury
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Avirup Chowdhury has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Paul H. Huang
The Institute of Cancer Research, London, UK
76 shared publications - Alexander T.J. Lee
The Christie NHS Foundation Trust, Manchester, United Kingdom
75 shared publications - Christopher P. Wilding
Division of Molecular Pathology, The Institute of Cancer Research, London, SW3 6JB, UK
75 shared publications - Cyril Fisher
University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
75 shared publications - Emma Perkins
Division of Molecular Pathology, The Institute of Cancer Research, London, United Kingdom
75 shared publications - Jessica Burns
Division of Molecular Pathology, The Institute of Cancer Research, London, United Kingdom
75 shared publications
Latest Publications
- Open Access
- 8 August 2025
- Published by Springer Nature in Communications Biology
- Vol. 8 (1) , 1185
Exploiting collateral sensitivity in the evolution of resistance to tyrosine kinase inhibitors in soft tissue sarcomas
Broad-spectrum multi-target tyrosine kinase inhibitors (mTKIs) are clinically approved for the treatment of soft tissue sarcomas (STS). However, acquired resistance inevitably arises in the majority of STS patients. There is therefore an urgent need to identify new strategies to overcome resistance and achieve durable treatment responses. Here we show that STS cells that acquire resistance to clinically relevant mTKIs are cross-resistant to one another and sequential treatment does not delay the acquisition of drug resistance. Instead, we find that en route to acquiring drug resistance, STS cells develop collateral sensitivities to alternative drugs. We demonstrate that the mTKI sitravatinib rapidly induces collateral sensitivity to the FGFR inhibitor infigratinib which can be exploited for adaptive therapy to suppress STS cell growth. This study provides proof-of-principle that collateral sensitivity may be an effective strategy for overcoming resistance to mTKIs and this novel approach should be explored in the design of future trials.
- 8 August 2025
- Published by Springer Nature in Communications Biology
- Vol. 8 (1) , 1185
Open AccessExploiting collateral sensitivity in the evolution of resistance to tyrosine kinase inhibitors in soft tissue sarcomas
Broad-spectrum multi-target tyrosine kinase inhibitors (mTKIs) are clinically approved for the treatment of soft tissue sarcomas (STS). However, acquired resistance inevitably arises in the majority of STS patients. There is therefore an urgent need to identify new strategies to overcome resistance and achieve durable treatment responses. Here we show that STS cells that acquire resistance to clinically relevant mTKIs are cross-resistant to one another and sequential treatment does not delay the acquisition of drug resistance. Instead, we find that en route to acquiring drug resistance, STS cells develop collateral sensitivities to alternative drugs. We demonstrate that the mTKI sitravatinib rapidly induces collateral sensitivity to the FGFR inhibitor infigratinib which can be exploited for adaptive therapy to suppress STS cell growth. This study provides proof-of-principle that collateral sensitivity may be an effective strategy for overcoming resistance to mTKIs and this novel approach should be explored in the design of future trials.
- Open Access
- 30 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S13 from Clinical Implications and Molecular Features of Extracellular Matrix Networks in Soft Tissue Sarcomas
Supplementary Table S13. Summary of univariable (UVA) and multivariable (MVA) Cox regression analyses assessing the association of clinicopathological factors and ssGSEA-derived proteoglycan score with overall survival (OS).
- 30 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S13 from Clinical Implications and Molecular Features of Extracellular Matrix Networks in Soft Tissue Sarcomas
Supplementary Table S13. Summary of univariable (UVA) and multivariable (MVA) Cox regression analyses assessing the association of clinicopathological factors and ssGSEA-derived proteoglycan score with overall survival (OS).
- Open Access
- 30 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Clinical Implications and Molecular Features of Extracellular Matrix Networks in Soft Tissue Sarcomas
Supplementary Table S4: Statistical comparisons between histological subtypes in cluster 1 (C1).
- 30 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Clinical Implications and Molecular Features of Extracellular Matrix Networks in Soft Tissue Sarcomas
Supplementary Table S4: Statistical comparisons between histological subtypes in cluster 1 (C1).
- Open Access
- 30 October 2024
- Published by American Association for Cancer Research (AACR)
Figure 1 from Clinical Implications and Molecular Features of Extracellular Matrix Networks in Soft Tissue Sarcomas
The matrisome and adhesome landscape of soft tissue sarcomas (STS). A, Annotated heatmap illustrating the unsupervised clustering (Pearson’s correlation distance) of 302 matrisome and adhesome components in the STS cohort. Top annotation panel correspond to histological subtype. The annotation on the (left) side shows proteins belonging to matrisome or adhesome databases and the breakdown into matrisome and adhesome functional classes. B, Heatmap showing matrisome and adhesome proteins uniquely upregulated (indicated by black boxes) in histological subtypes (false discovery rate <0.01, fold change ≥2), arranged by histological subtype. A selection of matrisome proteins which are upregulated in each histological subtype is shown. AS, angiosarcoma; ASPS, alveolar soft part sarcoma; CCS, clear cell sarcoma; DSRCT, desmoplastic small round cell tumor; ES, epithelioid sarcoma; RT, rhabdoid tumor.
- 30 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Clinical Implications and Molecular Features of Extracellular Matrix Networks in Soft Tissue Sarcomas
The matrisome and adhesome landscape of soft tissue sarcomas (STS). A, Annotated heatmap illustrating the unsupervised clustering (Pearson’s correlation distance) of 302 matrisome and adhesome components in the STS cohort. Top annotation panel correspond to histological subtype. The annotation on the (left) side shows proteins belonging to matrisome or adhesome databases and the breakdown into matrisome and adhesome functional classes. B, Heatmap showing matrisome and adhesome proteins uniquely upregulated (indicated by black boxes) in histological subtypes (false discovery rate <0.01, fold change ≥2), arranged by histological subtype. A selection of matrisome proteins which are upregulated in each histological subtype is shown. AS, angiosarcoma; ASPS, alveolar soft part sarcoma; CCS, clear cell sarcoma; DSRCT, desmoplastic small round cell tumor; ES, epithelioid sarcoma; RT, rhabdoid tumor.
- Open Access
- 30 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S11 from Clinical Implications and Molecular Features of Extracellular Matrix Networks in Soft Tissue Sarcomas
Supplementary Table S11. Statistical association of clinicopathological features with proteoglycan groups.
- 30 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S11 from Clinical Implications and Molecular Features of Extracellular Matrix Networks in Soft Tissue Sarcomas
Supplementary Table S11. Statistical association of clinicopathological features with proteoglycan groups.
- Open Access
- 30 October 2024
- Published by American Association for Cancer Research (AACR)
Table 1 from Clinical Implications and Molecular Features of Extracellular Matrix Networks in Soft Tissue Sarcomas
Clinicopathological characteristics of the cohort.
- 30 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Clinical Implications and Molecular Features of Extracellular Matrix Networks in Soft Tissue Sarcomas
Clinicopathological characteristics of the cohort.
- Open Access
- 30 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Clinical Implications and Molecular Features of Extracellular Matrix Networks in Soft Tissue Sarcomas
Supplementary Table S2: Matrisome and adhesome cluster membership.
- 30 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Clinical Implications and Molecular Features of Extracellular Matrix Networks in Soft Tissue Sarcomas
Supplementary Table S2: Matrisome and adhesome cluster membership.
- Open Access
- 30 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Clinical Implications and Molecular Features of Extracellular Matrix Networks in Soft Tissue Sarcomas
Supplementary Table S5. Summary of multivariable (MVA) analyses assessing association of clinicopathological factors and LCP1 tertiles with local recurrence-free survival (LRFS) and overall survival (OS). Clinicopathological factors which were significantly associated with survival in univariable analyses were included in the MVA model.
- 30 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Clinical Implications and Molecular Features of Extracellular Matrix Networks in Soft Tissue Sarcomas
Supplementary Table S5. Summary of multivariable (MVA) analyses assessing association of clinicopathological factors and LCP1 tertiles with local recurrence-free survival (LRFS) and overall survival (OS). Clinicopathological factors which were significantly associated with survival in univariable analyses were included in the MVA model.
- Open Access
- 30 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Clinical Implications and Molecular Features of Extracellular Matrix Networks in Soft Tissue Sarcomas
Supplementary Table S7: Summary of statistical tests to assess the association between clinicopathological features and dedifferentiated liposarcoma (DDLPS) subgroups.
- 30 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Clinical Implications and Molecular Features of Extracellular Matrix Networks in Soft Tissue Sarcomas
Supplementary Table S7: Summary of statistical tests to assess the association between clinicopathological features and dedifferentiated liposarcoma (DDLPS) subgroups.
- Open Access
- 30 October 2024
- Published by American Association for Cancer Research (AACR)
Figure 5 from Clinical Implications and Molecular Features of Extracellular Matrix Networks in Soft Tissue Sarcomas
Proteoglycan protein expression identifies a high-risk STS group. A, Summary of log-rank tests used to assess significant associations of matrisome-related gene sets with LRFS, MFS, and OS. The scores for each patient were obtained by taking the median expression focusing on 10 matrisome-related gene sets from the Molecular Signatures Database. B, Identities of the 11 proteoglycans included in the proteoglycan score. C, Kaplan–Meier plot of OS with stratification by the median expression of 11 proteoglycans in a combined UPS and DDLPS cohort (n = 92). D, Kaplan–Meier plot of OS with stratification by the ssGSEA score of 11 proteoglycans in a combined UPS and DDLPS cohort (n = 92). Hazard ratio, 95% CI, and P-values were determined by univariate Cox regression with a two-sided Wald test.
- 30 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from Clinical Implications and Molecular Features of Extracellular Matrix Networks in Soft Tissue Sarcomas
Proteoglycan protein expression identifies a high-risk STS group. A, Summary of log-rank tests used to assess significant associations of matrisome-related gene sets with LRFS, MFS, and OS. The scores for each patient were obtained by taking the median expression focusing on 10 matrisome-related gene sets from the Molecular Signatures Database. B, Identities of the 11 proteoglycans included in the proteoglycan score. C, Kaplan–Meier plot of OS with stratification by the median expression of 11 proteoglycans in a combined UPS and DDLPS cohort (n = 92). D, Kaplan–Meier plot of OS with stratification by the ssGSEA score of 11 proteoglycans in a combined UPS and DDLPS cohort (n = 92). Hazard ratio, 95% CI, and P-values were determined by univariate Cox regression with a two-sided Wald test.